Abstract: ObjectiveTo investigate the efficacy of adjuvant chemotherapy with fluorouracil combimed with oxaliplatin or paclitaxel sequentical S1 regimen after gastric cancer surgery. 
MethodsFrom January 2009 to September 2013， this retrospective analysis enrolled 166 cases of gastric cancer patients following D2 radical resection in Fujian Tumor Hospital， including 108 cases receiving fluorouracil plus oxaliplatin／paclitaxel biweekly regimen （control group） and 58 patients receiving fluorouracil plus oxaliplatin／paclitaxel biweekly regimen with sequential S1 （observation group）. Survival analysis was performed by KaplanMeier method. The median diseasefree survival （DFS） and overall survival （OS） of the two groups were compared. Cox proportional hazards model was used to analyze the prognostic factors by multivariate analysis. 
ResultsA total of 166 patients were followed up for 99929 months with a median followup of 403 months. The median DFS and OS of the observation group were 525 and 639 months， longer than 352 and 499 months of the control group， and the difference was statistically significant （P＜005）. Univariate analysis showed that pathological stage and sequential S1 therapy were related to prognosis. Gender， age， ECOG， histological differentiation， depth of invasion， lymph node status， location of primary tumor， chemotherapy regimen and chemotherapy cycle were not related to prognosis. Cox model multifactor analysis showed that pathological stage and sequential S1 therapy were independent factors affecting OS and DFS. 
ConclusionPostoperative adjuvant chemotherapy with fluorouracil plus oxaliplatin or paclitaxel with sequential S1 regimen can significantly improve the prognosis of gastric cancer， and pathological stage and sequential S1 therapy can be used as an independent prognostic indicator to guide adjuvant therapy after D2 radical surgery for gastric cancer.

Key words: Gastric cancer, D2 radical operation, Adjuvant chemotherapy